Abstract
It has been shown that UVB irradiation induces expression of COX-2 and up-regulation of COX-2 plays a functional role in UVB tumor promotion. In this study, we examined the cis-elements in the human COX-2 promoter that may be responsible for the UVB induction of COX-2. Analyses with the COX-2 promoter region revealed that the cyclic AMP responsive element near the TATA box was essential for both basal and UVB induced COX-2 expression. This was further supported by studies using a dominant negative mutant of CREB, which strongly inhibited the activity of COX-2 promoter. Electrophoretic mobility shift assays indicated that CREB and ATF-1 were the major proteins binding to the COX-2 CRE. CREB and ATF-1 were phosphorylated upon UVB treatment, and SB202190, a p38 MAPK inhibitor, decreased the phosphorylation of CREB/ATF-1 and suppressed COX-2 promoter activity. In contrast, treatment with forskolin, an activator of adenylyl cyclase, led to phosphorylation of CREB and ATF-1 and activation of COX-2 promoter. Finally, enhanced binding of phospho-CREB/ATF-1 to the COX-2 CRE was observed after UVB induction. Thus, one signaling pathway for UVB induction of human COX-2 involves activation of p38, subsequent phosphorylation of CREB/ATF-1, and activation of the COX-2 CRE through enhanced binding of phosphorylated CREB/ATF-1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- UVB:
-
ultraviolet B
- COX-2:
-
cyclooxygenase-2
- COX-1:
-
cyclooxygenase-1
- CRE:
-
cyclic AMP responsive element
- CREB:
-
CRE binding protein
- AP-1:
-
activator protein-1
- MAP:
-
mitogen-activated protein
- ERK:
-
extracellular signal-regulated protein kinase
- p38:
-
p38 MAP kinase
- ATF-1:
-
activating transcription factor
References
Alani R, Brown P, Binetruy B, Dosaka H, Rosenberg RK, Angel P, Karin M, Birrer MJ . 1991 Mol. Cell Biol. 11: 6286–6295
Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM . 1996 Cancer Res. 56: 2556–2560
Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE . 1988 J. Cell. Biol. 106: 761–717
Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ . 1996 Cell. Growth Differ. 7: 1013–1021
Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP . 1998 Carcinogenesis 19: 723–729
Chen W, Borchers AH, Dong Z, Powell MB, Bowden GT . 1998 J. Biol. Chem. 273: 32176–32181
Chen W, Bowden GT . 1999 Oncogene 18: 7469–7476
Chen W, Bowden GT . 2000 Mol. Carcinog. 28: 196–202
Chen W, Tang Q, Gonzales MS, Bowden GT . 2001 Oncogene in press
Dean JL, Brook M, Clark AR, Saklatvala J . 1999 J. Biol. Chem. 274: 264–269
DuBois RN, Awad J, Morrow J, Roberts II LJ, Bishop PR . 1994 J. Clin. Invest. 93: 493–498
DuBois RN, Radhika A, Reddy BS, Entingh AJ . 1996 Gastroenterology 110: 1259–1262
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN . 1994 Gastroenterology 107: 1183–1188
Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ . 1999 Mol. Carcinog. 25: 231–240
Harris RE, Namboodiri KK, Farrar WB . 1996 Epidemiology 7: 203–205
Huang C, Ma W, Bowden GT, Dong Z . 1996 J. Biol. Chem. 271: 31262–31268
Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM . 1998 Cancer Res. 58: 1208–1216
Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M . 2000 J. Biol. Chem. 275: 23627–23635
Inoue H, Tanabe T . 1998 Biochem. Biophys. Res. Commun. 244: 143–148
Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T . 1995 J. Biol. Chem. 270: 24965–24971
Isoherranen K, Punnonen K, Jansen C, Uotila P . 1999 Br. J. Dermatol. 140: 1017–1022
Kam PC, See AU . 2000 Anaesthesia 55: 442–449
Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR . 1991 J. Biol. Chem. 266: 12866–12872
Langenbach R, Loftin C, Lee C, Tiano H . 1999 Biochem. Pharmacol. 58: 1237–1246
Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR . 2000 Mol. Cell. Biol. 20: 4265–4274
Matsuura H, Sakaue M, Subbaramaiah K, Kamitani H, Eling TE, Dannenberg AJ, Tanabe T, Inoue H, Arata J, Jetten AM . 1999 J. Biol. Chem. 274: 29138–29148
Moatter T, Gerritsen ME . 1992 J. Cell. Physiol. 151: 571–578
Nusing RM, Klein T, Pfeilschifter J, Ullrich V . 1996 Biochem. J. 313: 617–623
O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD . 1996 J. Neurochem. 66: 2532–2540
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM . 1996 Cell 87: 803–809
Oshima T, Yoshimoto T, Yamamoto S, Kumegawa M, Yokoyama C, Tanabe T . 1991 J. Biol. Chem. 266: 13621–13626
O'Sullivan MG, Huggins Jr EM, Meade EA, DeWitt DL, McCall CE . 1992 Biochem. Biophys. Res. Commun. 187: 1123–1127
Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R . 1999 Carcinogenesis 20: 1939–1944
Reddy BS, Rao CV, Rivenson A, Kelloff G . 1993 Carcinogenesis 14: 1493–1497
Reddy BS, Rao CV, Seibert K . 1996 Cancer Res. 56: 4566–4569
Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J . 1998 FEBS Lett. 439: 75–80
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN . 1998 Cancer Res. 58: 362–366
Smalley WE, DuBois RN . 1997 Adv. Pharmacol. 39: 1–20
Smith W . 1997 Adv. Exp. Med. Biol 989–1011
Smith WL, Dewitt DL . 1996 Adv. Immunol. 62: 167–215
Staberg B, Wulf HC, Klemp P, Poulsen T, Brodthagen H . 1983 J. Invest. Dermatol. 81: 517–519
Strickland PT . 1986 J. Invest. Dermatol. 87: 272–275
Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ . 2000a J. Biol. Chem. 275: 14838–14845
Subbaramaiah K, Michaluart P, Sporn MB, Dannenberg AJ . 2000b Cancer Res. 60: 2399–2404
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN . 1998 Cell 93: 705–716
Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR . 2000 J. Biol. Chem. 275: 6259–6266
Xie W, Herschman HR . 1995 J. Biol. Chem. 270: 27622–27628
Xie W, Herschman HR . 1996 J. Biol. Chem. 271: 31742–31748
Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ . 1998 J. Biol. Chem. 273: 2424–2428
Acknowledgements
We thank Suzanne Stratton for critical review of the manuscript and many suggestions. We are also grateful for the invaluable secretary assistance of Anne Cione. This work was support in part by NIH grant CA27502.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tang, Q., Chen, W., Gonzales, M. et al. Role of cyclic AMP responsive element in the UVB induction of cyclooxygenase-2 transcription in human keratinocytes. Oncogene 20, 5164–5172 (2001). https://doi.org/10.1038/sj.onc.1204667
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204667
Keywords
This article is cited by
-
Molecular Insights into the Interaction of RONS and Thieno[3,2-c]pyran Analogs with SIRT6/COX-2: A Molecular Dynamics Study
Scientific Reports (2018)
-
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence
Cancer and Metastasis Reviews (2011)
-
Aberrant promoter hypermethylation in biliary tract carcinoma
Journal of Hepato-Biliary-Pancreatic Surgery (2006)
-
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma
British Journal of Cancer (2005)
-
Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines
Oncogene (2005)